All Stories

  1. Outcomes of two or more rounds of hematopoietic stem cell transplantation using total body irradiation for hematological malignancies
  2. Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3 ‐ ITD –Positive AML
  3. Absence of Pretransplant Peripheral Blasts is Favorable Factor in Allogeneic Stem Cell Transplantation for Advanced Acute Lymphoblastic Leukemia
  4. Treatment Outcomes of Adult B-Cell Acute Lymphoblastic Leukemia with Post-Transplant Relapse in the Era of Immunotherapeutic Agents
  5. Vaccine-Induced Anti-HBs Response is Associated with Protection Against Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Cell Transplantation: A Randomized Trial
  6. Significant clinical impact of immunosuppressive therapy termination after allogeneic haematopoietic stem cell transplantation
  7. Prognostic Impact of BK Polyomavirus Viremia Detected by Multiplex Plasma PCR Following Allogeneic Hematopoietic Cell Transplantation
  8. Novel Scoring System Using Geriatric Nutritional Risk Index, C-Reactive Protein, and Disease Status Predicts Survival After Second Allogeneic Stem Cell Transplantation
  9. Prognostic Value of C‐Reactive Protein/Platelet Ratio as a Biomarker Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Malignant Lymphoma
  10. Ponatinib/blinatumomab for relapsed Philadelphia chromosome-positive leukemia as a bridge to allogeneic transplantation
  11. Pre-transplant blinatumomab and/or inotuzumab ozogamicin therapy for relapsed/refractory acute lymphoblastic and B/myeloid mixed phenotype acute leukemia in adults
  12. Classical and Late‐Onset SOS/VOD After Allogeneic HSCT: A Japanese Transplant Registry Analysis
  13. Diamond–Blackfan anemia syndrome in an adult with RPS19 and DDX41 variants successfully treated with allogeneic stem cell transplantation: a case report
  14. Transplantation outcomes of TP53-mutant AML and MDS: a single transplantation center experience of 63 patients
  15. Quizartinib with donor lymphocyte infusion for post-transplant relapse of FLT3-ITD-positive acute myeloid leukemia
  16. Lower-dose post-transplant cyclophosphamide in haploidentical hematopoietic cell transplantation
  17. Overcoming post‐transplant graft failure and adenovirus infection in a patient with FLT3‐TKD‐mutated mixed‐phenotype acute leukemia: A case report
  18. Azacitidine and gemtuzumab ozogamicin as post-transplant maintenance therapy for high-risk hematologic malignancies
  19. Outcomes of Cessation of Nucleos(t)ide Analog Administration on Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Retrospective Study
  20. Recurrent DDX41 mutation in very late relapse after allogeneic stem cell transplantation
  21. Low‐ versus standard‐dose post‐transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation
  22. Azacitidine and gemtuzumab ozogamicin as post-transplant maintenance therapy for high-risk hematologic malignancies
  23. Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS
  24. Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia
  25. A third dose of COVID‐19 mRNA vaccine induces limited humoral response in stem cell transplant recipients who got two vaccine doses before transplant
  26. Central nervous system mucormycosis in a patient with hematological malignancy: A case report and review of the literature
  27. Phase I trial of myeloablative conditioning with three‐day total marrow and lymphoid irradiation for leukemia
  28. Dose-finding trial of azacitidine as post-transplant maintenance for high-risk MDS: a KSGCT prospective study
  29. Antithymocyte Globulin Potentially Could Overcome an Adverse Effect of Acute Graft-versus-Host Disease in Matched-Related Peripheral Blood Stem Cell Transplantation
  30. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia
  31. Paraplegia via hematogenous dissemination of Cunninghamella elegans (mucormycosis) after hematopoietic stem cell transplantation
  32. Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine/low-dose melphalan plus 4 Gy TBI versus fludarabine/ busulfan plus 4 Gy TBI
  33. Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis
  34. Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study
  35. Prognostic factors in salvage transplantation for graft failure following allogeneic hematopoietic stem cell transplantation
  36. A multicenter phase II study of intrabone single-unit cord blood transplantation without antithymocyte globulin
  37. Successful Cord Blood Transplantation for Idiopathic CD4<sup>+</sup> Lymphocytopenia
  38. Clinical Benefits of Preconditioning Intervention in Patients with Relapsed or Refractory Acute Myelogenous Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A Kanto Study of Group for Cell Therapy Multicenter Analysis
  39. T-cell receptor repertoire of cytomegalovirus-specific cytotoxic T-cells after allogeneic stem cell transplantation
  40. Intraventricular rupture of Aspergillus brain abscess during remission induction
  41. Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation
  42. Safety of total body irradiation using intensity-modulated radiation therapy by helical tomotherapy in allogeneic hematopoietic stem cell transplantation: a prospective pilot study
  43. Use of unapproved or off-label drugs in Japan for the treatment of graft-versus-host disease and post-transplant viral infection
  44. The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation
  45. Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT
  46. Nontuberculous mycobacterial bloodstream infections after allogeneic hematopoietic stem cell transplantation
  47. Geriatric nutritional risk index as a useful prognostic factor in second allogeneic hematopoietic stem cell transplantation
  48. Bone turnover markers as an aid to monitor osteoporosis following allogeneic hematopoietic stem cell transplantation
  49. Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemi...
  50. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century
  51. Outcomes and Prognostic Factors for Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A KSGCT Multicenter Analysis
  52. Late appearance of eosinophilia in myeloid blast phase of myeloid neoplasm with rearrangement of PDGFRβ
  53. Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia harboring t(1;19)(q23;p13.3); comparison with normal karyotype
  54. The sensitivity of the FLT3-ITD detection method is an important consideration when diagnosing acute myeloid leukemia
  55. Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre‐transplant conditioning using fludarabine, reduced‐dose cyclophosphamide, and low‐dose thymoglobulin: A KSGCT prospective study
  56. The emergence of rare nocardiosis following allogeneic hematopoietic stem cell transplantation in the era of molecular taxonomy
  57. Unmanipulated haploidentical hematopoietic stem cell transplantation using very low-dose antithymocyte globulin and methylprednisolone in adults with relapsed/refractory acute leukemia
  58. A case of polycythemia vera diagnosed after postextraction hemorrhage
  59. Allogeneic hematopoietic cell transplantation in patients with untreated acute myeloid leukemia: a KSGCT multicenter retrospective analysis
  60. Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia
  61. The Authors' Reply to "The Addition of Prophylactic Antibiotics Can Achieve a Favorable Outcome"
  62. Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis
  63. Nutritional risk index as a risk factor for breakthrough candidemia in allogeneic hematopoietic stem cell transplantation
  64. Disseminated adenovirus infection in a patient with relapsed refractory multiple myeloma undergoing autologous stem cell transplantation and pomalidomide/dexamethasone as salvage regimens
  65. Successful hematopoietic stem-cell mobilization with plerixafor plus granulocyte-colony stimulating factor in multiple myeloma patients treated with pomalidomide
  66. Geriatric nutritional risk index (GNRI) just before allogeneic hematopoietic stem cell transplantation predicts transplant outcomes in patients older than 50 years with acute myeloid leukemia in complete remission
  67. Co-activation of macrophages and T cells contribute to chronic GVHD in human IL-6 transgenic humanised mouse model
  68. Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial
  69. Fatal Neutropenic Enterocolitis Caused by <i>Stenotrophomonas maltophilia</i>: A Rare and Underrecognized Entity
  70. Reassessment of clinical implication of pretransplant surgical procedures for pulmonary invasive fungal lesions
  71. Clinical Efficacy of Prebiotics on Transplant-Related Complications
  72. Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia
  73. Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)
  74. Deregulated Mucosal Immune Surveillance through Gut-Associated Regulatory T Cells and PD-1+ T Cells in Human Colorectal Cancer
  75. Outcome of patients with acute undifferentiated leukemia after allogeneic hematopoietic stem cell transplantation
  76. Homozygous HLA-C1 is Associated with Reduced Risk of Relapse after HLA-Matched Transplantation in Patients with Myeloid Leukemia
  77. Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response—The final results of the D-first study
  78. A prospective multicenter phase II study of intrabone marrow transplantation of unwashed cord blood using reduced-intensity conditioning
  79. Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302)
  80. Outcomes after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia harboring t(7;11)(p15;p15)
  81. Predictive implications of albumin and C-reactive protein for progression to pneumonia and poor prognosis in Stenotrophomonas maltophilia bacteremia following allogeneic hematopoietic stem cell transplantation
  82. Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation
  83. Diagnostic open brain biopsy following initial negative results of cerebrospinal fluid assessment forToxoplasma
  84. Central nervous system infection following allogeneic hematopoietic stem cell transplantation
  85. Erythrocytosis after allogeneic hematopoietic stem cell transplantation
  86. Impact of Human Leukocyte Antigen Allele Mismatch in Unrelated Bone Marrow Transplantation with Reduced-Intensity Conditioning Regimen
  87. Extramedullary Gastric Relapse at the Time of Bone Marrow Relapse of Acute Lymphoblastic Leukemia after Allogeneic Bone Marrow Transplantation
  88. Mesenchymal Stem Cells: The First Approved Stem Cell Drug in Japan
  89. Central Nervous System Involvement at the Time of Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with a Poor Outcome in Patients with Acute Myeloid Leukemia
  90. the Safety and Efficacy of Deferasirox for the Transplant Patients with Iron Overload
  91. Clinical Impact of Pre-Transplant Microbial Diversity on Transplant Outcomes
  92. Mycophenolate mofetil is effective only for involved skin in the treatment for steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
  93. Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut
  94. Comparison of transplant outcomes and economic costs between biosimilar and originator filgrastim in allogeneic hematopoietic stem cell transplantation
  95. Clinical utility of high-flow nasal cannula oxygen therapy for acute respiratory failure in patients with hematological disease
  96. Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice
  97. Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: A nationwide retrospective study
  98. Comparison of Outcomes of 8/8 and 7/8 Allele–Matched Unrelated Bone Marrow Transplantation and Single-Unit Cord Blood Transplantation in Adults with Acute Leukemia
  99. Allogeneic hematopoietic stem cell transplant overcomes poor prognosis of acute myeloid leukemia with myelodysplasia-related changes
  100. Severe Hypoxemia in a Healthy Donor for Allogeneic Hematopoietic Stem Cell Transplantation after Only the First Administration of Granulocyte-Colony Stimulating Factor
  101. Occurrence of Donor Cell-derived Lymphoid Blast Crisis 24 Years Following Related Bone Marrow Transplantation for Chronic Myeloid Leukemia
  102. CD25 expression on residual leukemic blasts at the time of allogeneic hematopoietic stem cell transplant predicts relapse in patients with acute myeloid leukemia without complete remission
  103. Clinical impact of hematogones on outcomes of allogeneic hematopoietic stem cell transplantation
  104. Early-onset acute kidney injury is a poor prognostic sign for allogeneic SCT recipients
  105. Dasatinib-induced gastric antral vascular ectasia in a patient with acute lymphoblastic leukaemia
  106. The Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for Elderly Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) in the Era of Tyrosine Kinase Inhibitor (TKI) : A Single Institute Experience
  107. Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia
  108. Urinary Liver-Type Fatty Acid-Binding Protein Linked with Increased Risk of Acute Kidney Injury after Allogeneic Stem Cell Transplantation
  109. Toxic encephalopathy after exposure to azacitidine
  110. Contribution of Bone Marrow-Derived Hematopoietic Stem/Progenitor Cells to the Generation of Donor-Marker+ Cardiomyocytes In Vivo
  111. A Pyrrolo-Pyrimidine Derivative Targets Human Primary AML Stem Cells in Vivo
  112. Il2rg Gene-Targeted Severe Combined Immunodeficiency Pigs
  113. Incidence, risk factors, and clinical outcomes of cataracts following hematopoietic stem cell transplantation
  114. Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2rγnullhumanized mice
  115. Molecular monitoring of BAALC expression in patients with CD34-positive acute leukemia
  116. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML
  117. Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem Cells
  118. Cell Cycle Entry Potentiates Elimination of Chemotherapy-Resistant Human AML Stem Cells.
  119. Intracranial hemorrhage following allogeneic hematopoietic stem cell transplantation
  120. Quantitative Monitoring of T315I BCR-ABL Mutation by the Invader Assay.
  121. Molecular Monitoring of ERG and BAALC as Minimal Residual Disease Markers in Patients with Acute Leukemia.
  122. Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma
  123. High Mobility Group Protein-B1 Interacts with Sterol Regulatory Element-binding Proteins to Enhance Their DNA Binding
  124. p53 Involvement in the Pathogenesis of Fatty Liver Disease
  125. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression
  126. p53 Activation in Adipocytes of Obese Mice